

Liqmeds Worldwide limited Balance Sheet as at March 31, 2026	
--	--

Particulars	Note No.	GBP-Thousand	
		As at March 31	
		2026	2025
ASSETS:			
Current Assets:			
Financial Assets:			
Trade Receivables	1	37,566	13,127
Cash and Cash Equivalents	2	573	3,409
Other Current Assets	3	112	2
		38,251	16,538
Total		38,251	16,538
EQUITY AND LIABILITIES:			
Equity:			
Equity Share Capital	4	0	0
Other Equity	5	36,798	16,062
		36,798	16,062
Current Liabilities:			
Financial Liabilities:			
Trade Payables	6	739	476
Other Current Liabilities	7	714	-
		1,453	476
Total		38,251	16,538
For and on behalf of the Board			
Sd/-			
Director			
Dated : May 15, 2026			

Liqmeds Worldwide limited Statement of Profit and Loss for the year ended March 31, 2026			
Particulars	Note No.	GBP-Thousand	
		Year ended March 31	
		2026	2025
Revenue from Operations	8	22,602	14,243
Other Income	9	-	178
Total Income		22,602	14,421
EXPENSES:			
Cost of Materials Consumed	10	-	6
Finance Costs	11	1	(14)
Other Expenses	12	283	254
Net Loss [Gain] on foreign currency transactions		868	122
Total Expenses		1,152	367
Profit before Tax		21,450	14,054
Less: Tax Expense:			
Current Tax		714	-
		714	-
Profit for the year		20,736	14,054
For and on behalf of the Board			
Sd/-			
Director			
Dated : May 15, 2026			

Liqmeds Worldwide limited Notes to the Financial Statements		
	GBP-Thousand	
	As at March 31	
	2026	2025
Note: 1-Trade receivables:		
Trade debtors	37,566	13,127
Total	37,566	13,127
Note: 2-Cash and Bank Balances:		
Cash and Cash Equivalents:		
Cash on Hand [GBP: 100 {as at March 31, 2025: GBP 100}]	0	0
Balances with Banks	573	3,409
Total	573	3,409
Note: 3-Other Current Assets:		
Balances with Statutory Authorities	112	-
Advances to Suppliers	-	2
Total	112	2
Note: 4-Equity Share Capital:		
Issued, Subscribed and Paid-up:		
Equity Shares [GBP: 100 {as at March 31, 2025: GBP 100}]	0	0
	0	0
Note: 5-Other Equity:		
Retained Earnings:		
Balance as per last Balance Sheet	16,062	2,008
Add: Profit for the year	20,736	14,054
Total	36,798	16,062
Note: 6-Trade Payables:		
Others	739	476
Total	739	476
Note: 7-Other Current Liabilities:		
Payable to Statutory Authorities	714	-
Total	714	-

Liqmeds Worldwide limited		
Notes to the Financial Statements		
	GBP-Thousand	
	Year ended March 31	
	2026	2025
Note: -8-Revenue from Operations:		
Sale of Products	22,602	14,243
Total	22,602	14,243
Note: 9-Other Income:		
Other Non-operating Income	-	178
Total	-	178
Note: 10-Cost of Materials Consumed:		
Raw Materials:		
Stock at commencement	-	
Add: Purchases	-	6
	-	6
Less: Stock at close	-	6
	-	-
Packing Materials consumed	-	6
Total	-	6
Note: 11-Finance Cost:		
Interest expense	-	(14)
Bank commission & charges [as at March 31, 2025: GBP 273]	1	0
Total	1	(14)
Note: 12-Other Expenses:		
Legal and Professional Fees	1	19
Freight and forwarding on sales	18	-
Bad debts written off	120	-
Other Research expense	144	77
Miscellaneous Expenses	-	159
Total	283	254